Fig. 1 · Structure

Cat. No.: A10853
CAS No.: 67920-52-9
Formula: C₉H₉O₅.Na
Mol. Weight: 220.2

Documents & Downloads

Sodium Danshensu

Name: Sodium Danshensu
Brand: Adooq Bioscience
SKU: A10853
Availability: InStock

Cat. No. A10853 CAS 67920-52-9

Sodium danshensu is a sodium salt of danshensu from the widely used Chinese herb Danshen (Salvia miltiorrhiza Bunge). In vitro and in vivo studies revealed that danshensu possessed diverse pharmacological effects, including relaxation of coronary artery, anticoagulation, protection of myocardial ischemia-reperfusion injury, and antiarrhythmia activities

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target	Activity	Value
P450

In Vitro Studies

Danshensu was tested directly with COX-2 in reaction buffer, yielding an IC50 value of approximately 44 µM. In mouse C2C12 cells exposed to Sodium Danshensu for 72 h, MTT-assessed viability was 96.8% at concentrations up to 100 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

COX-2 Activity Assay

Cell-based study · COX-2 [1]

Danshensu was incubated directly with COX-2 in reaction buffer at 20 to 200 µM, with water serving as control. The COX-2 activity assay yielded an IC50 value of approximately 44 µM.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
COX-2 activity	IC50 IC50 value of approximately 44 µM	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 20 to 200 µM
Exposure duration: for 10 min. Then, AA was added as substrate and the reaction continued for another 2 min.
Method: incubated directly with COX-1 or COX-2 in reaction buffer
Vehicle: water

Methods and source locations

Compound reported in the paper: Danshensu

The paper names Danshensu without stating the salt or form; not verified as the sodium form supplied as A10853. No dose conversion or lot validation.

Results > Effects on COX and possible mechanisms (S14); Materials and Methods > Effects of Danshensu on COX activity and expression (S82, S84)

COX-2 activity: COX-2 activity; comparator: the same volume of water serving as control — Results > Effects on COX and possible mechanisms (S14)

Cell Viability in Mouse Myoblasts

Cell-based study · mouse C2C12 cells [2]

Mouse C2C12 cells were exposed to Sodium Danshensu in fresh medium for 72 h. MTT-assessed cell viability was 96.8% at concentrations up to 100 μM.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Cell viability was evaluated using the MTT assay (n = 3).	cell viability 96.8%	[2]

Literature-Reported Treatment Conditions

Treatment concentration: 1–100 μM
Exposure duration: 72 h
Method: fresh medium containing various doses of DS, DSS, and DG
Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: Sodium Danshensu; Compound label in the paper: Danshensu

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Cell viability assay (S9, S10); RESULTS > Effect of DSS in skeletal muscle cells (S63); FIGURE 1 legend (S138, S139, S141, S142)

Cell viability was evaluated using the MTT assay (n = 3).: Cell viability was evaluated using the MTT assay (n = 3).; comparator: control — RESULTS > Effect of DSS in skeletal muscle cells (S63); FIGURE 1 legend (S139)

In Vivo Studies

In male C57BL/6 mice with DG-induced accelerated aging, intraperitoneal Sodium Danshensu administered alongside DG significantly recovered the decrease in grip strength compared with the DG treatment group. In adult BALB/c mice given oral Danshensu before SARS-CoV-2 S-induced ALI, lung histological scores in the 50 mg/kg and 100 mg/kg groups were significantly lower than in the SARS-CoV-2 S group. [2,3]

Grip Strength in an Accelerated Aging Mouse Model

Animal study · Male C57BL/6 mice; DG‐induced accelerated aging model; n = 6 per group [2]

Male C57BL/6 mice with DG-induced accelerated aging received Sodium Danshensu intraperitoneally at 50 mg/kg or 100 mg/kg alongside DG. Compared with the DG treatment group, Sodium Danshensu significantly recovered the DG-induced decrease in grip strength.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Grip strength testing	Reported result DSS administration (50–100 mg/kg) significantly recovered the decrease in grip strength induced by DG treatment	[2]

Conditions shared by the study groups

Route: intraperitoneally
Treatment course: After 5 weeks of DG administration, the mice were intraperitoneally injected daily with DSS (50 mg/kg) or DSS (100 mg/kg) along with DG (300 mg/kg) for 4 weeks.

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Sodium Danshensu 50 mg/kg; 100 mg/kg	DG administration	DSS administration (50–100 mg/kg) significantly recovered the decrease in grip strength induced by DG treatment	[2]

Sodium Danshensu 50 mg/kg; 100 mg/kg: Model: Male C57BL/6 mice; DG‐induced accelerated aging model; n = 6 per group; Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: Sodium Danshensu; Compound label in the paper: Danshensu

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Cell viability assay (S9); MATERIALS AND METHODS > Calcium and reactive oxygen species (ROS) assay (S32); MATERIALS AND METHODS > Immunocytochemistry (S35); MATERIALS AND METHODS > Animal experiment (S44, S45, S47, S48); RESULTS > DSS administration ameliorates symptoms of sarcopenia (S117, S126, S127); FIGURE 6 legend (S188, S192, S193)

Grip strength testing: Grip strength testing; comparator: DG administration — RESULTS > DSS administration ameliorates symptoms of sarcopenia (S127); FIGURE 6 legend (S188)

Sodium Danshensu 50 mg/kg; 100 mg/kg · MATERIALS AND METHODS > Animal experiment (S48); RESULTS > DSS administration ameliorates symptoms of sarcopenia (S127); FIGURE 6 legend (S192)

Lung Histological Scores in a Mouse ALI Model

Animal study · Adult BALB/c mice (male, 6–8 weeks, 20 ± 2 g); ALI model was induced by SARS-CoV-2 S via trachea; groups (n = 8) [3]

Adult BALB/c mice received oral Danshensu before induction of ALI by SARS-CoV-2 S. Lung histological scores were significantly lower in the 50 mg/kg and 100 mg/kg groups than in the SARS-CoV-2 S group.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
lung histological scores	Reported result lung histological scores in the Danshensu 50 mg/kg and 100 mg/kg groups; significantly lower than in the SARS-CoV-2 S group (Fig. 3a, d) (all P < 0.05).	[3]

Conditions shared by the study groups

Route: orally
Treatment course: once daily for 7 continuous days; ALI model was induced by SARS-CoV-2 S via trachea after the last treatment
Vehicle: distilled water

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Danshensu 25 mg/kg/d, 50 mg/kg/d, or 100 mg/kg/d	SARS-CoV-2 S group received distilled water orally.	lung histological scores in the Danshensu 50 mg/kg and 100 mg/kg groups; significantly lower than in the SARS-CoV-2 S group (Fig. 3a, d) (all P < 0.05).	[3]

Danshensu 25 mg/kg/d, 50 mg/kg/d, or 100 mg/kg/d: Model: Adult BALB/c mice (male, 6–8 weeks, 20 ± 2 g); ALI model was induced by SARS-CoV-2 S via trachea; groups (n = 8)

Methods and source locations

Compound reported in the paper: Danshensu

The paper names Danshensu without stating the salt or form; not verified as the sodium form supplied as A10853. No dose conversion or lot validation.

Materials and methods > Animals (S5, S10, S11, S12, S13, S14, S15); Materials and methods > Hematoxylin-eosin (H&E) staining and immunohistochemistry (S18); Materials and methods > SARS-CoV-2 S-induced ALI (S40); Results > Danshensu could prevent SARS-CoV-2 S protein-induced acute lung inflammation (S59)

lung histological scores: lung histological scores; comparator: SARS-CoV-2 S group received distilled water orally. — Results > Danshensu could prevent SARS-CoV-2 S protein-induced acute lung inflammation (S59)

Danshensu 25 mg/kg/d, 50 mg/kg/d, or 100 mg/kg/d · Materials and methods > Animals (S13, S14, S15); Results > Danshensu could prevent SARS-CoV-2 S protein-induced acute lung inflammation (S59)

Specifications

Manufacturer	Adooq Bioscience
CAS Number	67920-52-9
Formula	C₉H₉O₅.Na
Molecular Weight	220.2
SMILES	C1=CC(=C(C=C1CC(C(=O)[O-])O)O)O.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	Warmed: 7 mg/mL (31.79 mM)
Water	2 mg/mL (9.08 mM)
Ethanol	Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Yu C, Qi D, Lian W, et al. Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. PLoS One (2014). PMID: 25375124 DOI: 10.1371/journal.pone.0110124 Source material
[2] Lim P, Woo SW, Han J, et al. Danshensu sodium salt alleviates muscle atrophy via CaMKII-PGC1α-FoxO3a signaling pathway in D-galactose-induced models. FASEB J (2025). PMID: 39835720 DOI: 10.1096/fj.202402158R Source material
[3] Wang W, Li SS, Xu XF, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin (2022). PMID: 34267343 DOI: 10.1038/s41401-021-00714-4 Source material

Documents & Downloads

Sodium Danshensu

Select a Size

Package Sizes

DMSO Solution